Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2020 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

PV-10® Abstract Previously Accepted for Presentation at Terminated American Association for Cancer Research (AACR) Annual Meeting 2020

KNOXVILLE, TN, March 17, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today said that data from ongoing research into investigational lysosomal-targeting cancer immunotherapy PV-10 (rose bengal...
August 07, 2019 06:30 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics Reports Second Quarter 2019 Financial Results

- Initiated Phase 2 EMERGE trial of vopratelimab - - Completed enrollment of Phase 1 trial of JTX-4014 - - Updated strategic collaboration and established new licensing agreement with...
November 10, 2018 12:20 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

- Characterization of emerging ICOS hi CD4 T cells from responding patients provides rationale for JTX-2011 combination therapies - CAMBRIDGE, Mass., Nov. 10, 2018 (GLOBE NEWSWIRE) -- Jounce...
March 26, 2014 07:30 ET | Source: Zyomyx

Zyomyx Receives $7.5 Million From UNITAID to Launch Rapid, Service-Free Point-of-Care CD4 Test

FREMONT, Calif., March 26, 2014 (GLOBE NEWSWIRE) -- Zyomyx, Inc. has been awarded US$7.5 million from UNITAID to commercialize its quantitative MyT4™ point-of-care CD4 test, designed to guide...
January 09, 2014 07:30 ET | Source: Zyomyx

Zyomyx Receives CE Mark for Its New MyT4(TM) Point-of-Care CD4 Test

FREMONT, Calif., Jan. 9, 2014 (GLOBE NEWSWIRE) -- Zyomyx, Inc., a provider of innovative point-of-care diagnostic tests, announced today that it received the CE Mark for its MyT4™ point-of-care...